DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $253K a year earlier. Over 3 fiscal years it compounded at +46.5% a year.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 258K USD
- Year-over-year change
- +9.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 258K | +9.3% |
| FY2024 | 2024-12-31 | 236K | -36.0% |
| FY2023 | 2023-12-31 | 369K | +350.0% |
| FY2022 | 2022-12-31 | 82K | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 net receivables of $0 is the 6th highest of the 7 companies compared; the peer median is $2.48M.
- Its year-over-year change of -100.0% is the lowest of 4, against a peer median of +1.6%.
- Net receivables amounts to 0.0% of total assets for DMAC, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $62.54M | +1.6% | +5.3% | 17.3% | |
| Mar 2026 | $20M | — | — | 4.8% | |
| Jun 2026 | $3.93M | — | -38.3% | 0.3% | |
| Mar 2026 | $1.03M | -41.1% | — | 0.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $709K | +96.4% | — | 0.2% |
| Mar 2026 | $0 | -100.0% | +46.5% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DMAC) | $2.48M | +1.6% | -16.5% | 0.3% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.